ImmunityBio (IBRX) Operating Leases (2019 - 2026)

ImmunityBio (IBRX) has 8 years of Operating Leases data on file, last reported at $40.8 million in Q1 2026.

• On a quarterly basis, Operating Leases rose 0.53% year-over-year to $40.8 million in Q1 2026; TTM through Mar 2026 was $40.8 million, a 0.53% increase from a year earlier, with the FY2025 full-year figure at $33.4 million, down 3.95% from the prior year.
• Operating Leases for Q1 2026 stood at $40.8 million, up from $33.4 million in the prior quarter.
• Over the last five years, Operating Leases for IBRX reached as high as $52.1 million in Q2 2022 and fell as low as $33.4 million in Q4 2025.
• Historically, Operating Leases has averaged $42.0 million across 5 years, with a median of $40.6 million in 2025.
• Across the five-year window, Operating Leases soared 140.17% in 2022 and slipped 23.04% in 2023, its largest moves.
• Year by year, Operating Leases stood at $48.0 million in 2022, then dropped by 16.7% to $39.9 million in 2023, then dropped by 12.82% to $34.8 million in 2024, then declined by 3.95% to $33.4 million in 2025, then climbed by 21.9% to $40.8 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $40.8 million in Q1 2026, $33.4 million in Q4 2025, and $34.1 million in Q3 2025.